Evaluation of the antidepressant effect of Laurus nubilis essential oil in animal models of depression in male mice

2016 ◽  
Keyword(s):  
Animal Models ◽  
Essential Oil ◽  
Antidepressant Effect ◽  
Male Mice ◽  
Animal Models Of Depression

Preclinical evidence for the role of serotonin receptor-subtypes in depression

1992 ◽  
Vol 4 (2) ◽  
pp. 40-45
Author(s):  
B. Olivier ◽  
J. Schipper ◽  
J.A.M. van der Heyden ◽  
A. van Hest ◽  
J. Mos ◽  
...  
Keyword(s):  
Animal Models ◽  
Clinical Research ◽  
Serotonin Receptor ◽  
Antidepressant Effect ◽  
Receptor Subtypes ◽  
Research Support ◽  
Receptor Agonists ◽  
Animal Models Of Depression ◽  
Literature Evidence

SummarySerotonin (5-HT) plays an important role in depression and specific 5-HT reuptake blockers appear to be clinically important antidepressants. It is unclear however, which serotonergic mechanism is involved in the antidepressant effect, certainly when regarding the existence of at least seven 5-HT receptor subtypes. By testing different 5-HT ligands in two animal models of depression (forced swimming and DRL72-S test) and comparison with data from literature, evidence is provided for potential antidepressant qualities of 5-HT1A receptor-agonists and 5-HT1C receptor-antagonists. Compounds binding to 5-HT1B, 5-HT2 and 5-HT3 receptors do not have an antidepressant profile. Results of clinical research support the predicted antidepressive effects of 5-HT1A receptor-agonists.

scholarly journals Potentials of Curcumin as an Antidepressant

2009 ◽  
Vol 9 ◽  
pp. 1233-1241 ◽  
Author(s):  
S.K. Kulkarni ◽  
Ashish Dhir ◽  
Kiran Kumar Akula
Keyword(s):  
Major Depression ◽  
Animal Models ◽  
Monoamine Oxidase ◽  
Molecular Mechanisms ◽  
Antidepressant Effect ◽  
Symptoms Of Depression ◽  
Animal Models Of Depression ◽  
Antidepressant Efficacy ◽  
Oxidase Enzyme ◽  
Human Illness

Major depression, a debilitating psychiatric disorder, is predicted to be the second most prevalent human illness by the year 2020. Various antidepressants, ranging from monoamine oxidase inhibitors to recently developed dual reuptake inhibitors, are prescribed for alleviating the symptoms of depression. Despite the availability of these blockbuster molecules, approximately 30% of depressed patients do not respond to the existing drug therapies and the remaining 70% fails to achieve complete remission. Moreover, antidepressants are associated with a plethora of side effects and drug-drug/drug-food interactions. In this context, novel approaches are being tried to find more efficacious and safer drugs for the treatment of major depression. Curcumin is one such molecule that has shown promising efficacy in various animal models of major depression. Although the mechanism of the antidepressant effect of curcumin is not fully understood, it is hypothesized to act through inhibiting the monoamine oxidase enzyme and modulating the release of serotonin and dopamine. Moreover, evidences have shown that curcumin enhances neurogenesis, notably in the frontal cortex and hippocampal regions of the brain. The use of curcumin in clinics for the treatment of major depression is limited due to its poor gastrointestinal absorption. The present review attempts to discuss the pharmacological profile along with molecular mechanisms of the antidepressant effect of curcumin in animal models of depression. A need for clinical trials in order to explore the antidepressant efficacy and safety profile of curcumin is emphasized.

The effect of the essential oil ofEugenia caryophyllatain animal models of depression and locomotor activity

2013 ◽  
Vol 16 (5) ◽  
pp. 233-238 ◽  
Author(s):  
Ashish K. Mehta ◽  
Sumita Halder ◽  
Naresh Khanna ◽  
Om P. Tandon ◽  
Krishna K. Sharma
Keyword(s):  
Locomotor Activity ◽  
Animal Models ◽  
Essential Oil ◽  
Animal Models Of Depression

Antidepressant Effect of Thymoquinone in Animal Models of Depression

Drug Research ◽  
2014 ◽  
Vol 65 (09) ◽  
pp. 490-494 ◽  
Author(s):  
M. Aquib ◽  
A. Najmi ◽  
M. Akhtar
Keyword(s):  
Animal Models ◽  
Antidepressant Effect ◽  
Animal Models Of Depression

scholarly journals Antidepressant Activity of Nardostachys jatamansi Extract in Animal Models of Depression

2021 ◽  
pp. 102-111
Author(s):  
Faraz Saleem ◽  
Muhammad Owais Ismail ◽  
Zahida Memon ◽  
Faraz Arif
Keyword(s):  
Animal Models ◽  
Effective Dose ◽  
Mental Health Problems ◽  
Test Group ◽  
Antidepressant Activity ◽  
Antidepressant Effect ◽  
Animal Models Of Depression ◽  
Nardostachys Jatamansi ◽  
Immobility Time ◽  
Wide Range

Background: Depression refers to a wide range of mental health problems characterized by the loss of interest in routine activities, low mood and a range of associated emotional, cognitive, physical and behavioral symptoms. It is one of the major causes of mortality as tendency of suicidal attacks are exhibited in these patients. The diagnosis of depressive patients is very complicated in many cases and they do not respond to rational clinical prescription. In traditional medicine, Nardostachys jatamansi has been used as stimulant, antispasmodic, laxative and antiepileptic in ayurvedic and unani systems of medicine. The objective of our study was to evaluate and compare the antidepressant activity of N. jatamansi extract with fluoxetine in animal models of depression. Methodology: It was a preclinical experimental study in which Total 100 BALB/c mice divide into 14 groups i.e. Group 1 & 2 control 0.9% NaCl i.p for forced swimming test (FST) and tail suspension test (TST) respectively, Group 3 & 4 Fluoxetine 0.5 mg/kg i.p for FST and TST respectively, Group 5, 6 & 7 of N. jatamansi 125, 250 and 500 mg/kg respectively for FST, Group 8, 9 & 10 N. jatamansi 125, 250 and 500 mg/kg respectively for TST, Group 11 N. jatamansi (most effective dose) for Locomotor Test, Group 12 NaCl 0.9% for Yohimbine Potentiation Test (YPT), Group 13 Fluoxetine 0.5 mg/kg for YPT and Group 14 Received extract of N. jatamansi (most effective dose) for YPT. Antidepressant activity of N. jatamansi extract at different doses after induction of depression via FST and TST was recorded. Moreover the antidepressant effect was confirmed by locomotor test. YPT was also applied to comment on possible underlying mechanism. Results: In our study 250 mg/kg and 500 mg/kg doses of N. jatamansi showed significant reduction in immobility time when compared to controls and 500 mg/kg showed significant reduction as compared to group given fluoxetine in FST model. All the groups in TST model showed significant reduction in immobility time when compared to controls and fluoxetine given group. N. jatamansi at the dose of 500 mg/kg was found to be most effective in both the models. No significant change in locomotor activity was found in locomotor test. The percentage mortality of 50% was observed in N. jatamansi group using yohimbine potentiation test. Conclusion: In our study Nardostachys jatamansi showed significant reduction in immobility time when compared to controls and fluoxetine.

scholarly journals Elevated Brain Fatty Acid Amide Hydrolase Induces Depressive-Like Phenotypes in Rodent Models: A Review

2021 ◽  
Vol 22 (3) ◽  
pp. 1047
Author(s):  
Dorsa Rafiei ◽  
Nathan J. Kolla
Keyword(s):  
Depressive Symptoms ◽  
Fatty Acid ◽  
Animal Models ◽  
Fatty Acid Amide Hydrolase ◽  
Acid Amide ◽  
Endocannabinoid System ◽  
Animal Models Of Depression ◽  
Amide Hydrolase ◽  
Fatty Acid Amide

Altered activity of fatty acid amide hydrolase (FAAH), an enzyme of the endocannabinoid system, has been implicated in several neuropsychiatric disorders, including major depressive disorder (MDD). It is speculated that increased brain FAAH expression is correlated with increased depressive symptoms. The aim of this scoping review was to establish the role of FAAH expression in animal models of depression to determine the translational potential of targeting FAAH in clinical studies. A literature search employing multiple databases was performed; all original articles that assessed FAAH expression in animal models of depression were considered. Of the 216 articles that were screened for eligibility, 24 articles met inclusion criteria and were included in this review. Three key findings emerged: (1) FAAH expression is significantly increased in depressive-like phenotypes; (2) genetic knockout or pharmacological inhibition of FAAH effectively reduces depressive-like behavior, with a dose-dependent effect; and (3) differences in FAAH expression in depressive-like phenotypes were largely localized to animal prefrontal cortex, hippocampus and striatum. We conclude, based on the animal literature, that a positive relationship can be established between brain FAAH level and expression of depressive symptoms. In summary, we suggest that FAAH is a tractable target for developing novel pharmacotherapies for MDD.

scholarly journals Progesterone after Estradiol Modulates Shuttle-Cage Escape by Facilitating Volition

2015 ◽  
Vol 9s1 ◽  
pp. JEN.S32735
Author(s):  
Darryl J. Mayeaux ◽  
Sarah M. Tandle ◽  
Sean M. Cilano ◽  
Matthew J. Fitzharris
Keyword(s):  
Depressive Symptoms ◽  
Animal Models ◽  
Electric Shock ◽  
Ovarian Hormones ◽  
Learning Task ◽  
The Other ◽  
Female Rats ◽  
Animal Models Of Depression ◽  
Escape Learning

In animal models of depression, depression is defined as performance on a learning task. That task is typically escaping a mild electric shock in a shuttle cage by moving from one side of the cage to the other. Ovarian hormones influence learning in other kinds of tasks, and these hormones are associated with depressive symptoms in humans. The role of these hormones in shuttle-cage escape learning, however, is less clear. This study manipulated estradiol and progesterone in ovariectomized female rats to examine their performance in shuttle-cage escape learning without intentionally inducing a depressive-like state. Progesterone, not estradiol, within four hours of testing affected latencies to escape. The improvement produced by progesterone was in the decision to act, not in the speed of learning or speed of escaping. This parallels depression in humans in that depressed people are slower in volition, in their decisions to take action.

Sign in / Sign up

Export Citation Format

Share Document